PharmGKB summary: Very important pharmacogene information for GSTT1

Pharmacogenetics and Genomics

Volumn 22, Issue 8, 2012, Pages 646-651

  Thorn, Caroline F ^a   Ji, Yuan ^b   Weinshilboum, Richard M ^b   Altman, Russ B ^a   Klein, Teri E ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE T1; TRICHLOROETHYLENE; XENOBIOTIC AGENT;

ARTICLE; BLADDER CANCER; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CAUCASIAN; CELL DAMAGE; DETOXIFICATION; DRUG INTOXICATION; GENE DELETION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; LUNG CANCER; META ANALYSIS (TOPIC); NULL ALLELE; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84863851088     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283527c02     Document Type: Article

References (82)

1. Landi S. Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutat Res 2000; 463:247-283.
2. Josephy PD, Kent M, Mannervik B. Single-nucleotide polymorphic variants of human glutathione transferase T1-1 differ in stability and functional properties. Arch Biochem Biophys 2009; 490:24-29.
3. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30:445-600.
4. Kim SD, Lee JH, Hur EH, Kim DY, Lim SN, Choi Y, et al. Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17:1222-1230.
5. Wheeler HE, Gamazon ER, Stark AL, O'Donnell PH, Gorsic LK, Huang RS, et al. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J 2011[Epub ahead of print].
6. Moyer AM, Sun Z, Batzler AJ, Li L, Schaid DJ, Yang P, et al. Glutathione pathway genetic polymorphisms and lung cancer survival after platinumbased chemotherapy. Cancer Epidemiol Biomarkers Prev 2010; 19: 811-821.
7. Teixeira RL, Morato RG, Cabello PH, Muniz LM, Moreira Ada S, Kritski AL, et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz 2011; 106:716-724.
8. Thier R, Wiebel FA, Hinkel A, Burger A, Bruning T, Morgenroth K, et al. Species differences in the glutathione transferase GSTT1-1 activity towards the model substrates methyl chloride and dichloromethane in liver and kidney. Arch Toxicol 1998; 72:622-629. (Pubitemid 28523090)
9. Bruning T, Lammert M, Kempkes M, Thier R, Golka K, Bolt HM. Influence of polymorphisms of GSTM1 and GSTT1 for risk of renal cell cancer in workers with long-term high occupational exposure to trichloroethene. Arch Toxicol 1997; 71:596-599. (Pubitemid 27339063)
10. Zhao C, Vodicka P, Sram RJ, Hemminki K. DNA adducts of 1,3-butadiene in humans: relationships to exposure, GST genotypes, single-strand breaks, and cytogenetic end points. Environ Mol Mutagen 2001; 37:226-230. (Pubitemid 32411128)
11. Navarro SL, Chang JL, Peterson S, Chen C, King IB, Schwarz Y, et al. Modulation of human serum glutathione S-transferase A1/2 concentration by cruciferous vegetables in a controlled feeding study is influenced by GSTM1 and GSTT1 genotypes. Cancer Epidemiol Biomarkers Prev 2009; 18:2974-2978.
12. De Bruin WC, Wagenmans MJ, Peters WH. Expression of glutathione S-transferase alpha, P1-1 and T1-1 in the human gastrointestinal tract. Jpn J Cancer Res 2000; 91:310-316. (Pubitemid 30198171)
13. Wang L, Groves MJ, Hepburn MD, Bowen DT. Glutathione S-transferase enzyme expression in hematopoietic cell lines implies a differential protective role for T1 and A1 isoenzymes in erythroid and for M1 in lymphoid lineages. Haematologica 2000; 85:573-579. (Pubitemid 30450935)
14. Simic T, Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, Mimic-Oka J. Glutathione S-transferases in kidney and urinary bladder tumors. Nat Rev Urol 2009; 6:281-289.
15. Butler MW, Hackett NR, Salit J, Strulovici-Barel Y, Omberg L, Mezey J, et al. Glutathione S-transferase copy number variation alters lung gene expression. Eur Respir J 2011; 38:15-28.
16. Van Lieshout EM, Tiemessen DM, Roelofs HM, Peters WH. Nonsteroidal anti-inflammatory drugs enhance glutathione S-transferase theta levels in rat colon. Biochim Biophys Acta 1998; 1381:305-311. (Pubitemid 28386815)
17. Whittington A, Vichai V, Webb G, Baker R, Pearson W, Board P. Gene structure, expression and chromosomal localization of murine theta class glutathione transferase mGSTT1-1. Biochem J 1999; 337 (Pt 1):141-151. (Pubitemid 29039094)
18. Sherratt PJ, Manson MM, Thomson AM, Hissink EA, Neal GE, van Bladeren PJ, et al. Increased bioactivation of dihaloalkanes in rat liver due to induction of class theta glutathione S-transferase T1-1. Biochem J 1998; 335 (Pt 3): 619-630. (Pubitemid 28515416)
19. Cotton SC, Sharp L, Little J, Brockton N. Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol 2000; 151:7-32. (Pubitemid 30470391)
20. Zhang ZJ, Hao K, Shi R, Zhao G, Jiang GX, Song Y, et al. Glutathione S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) null polymorphisms, smoking, and their interaction in oral cancer: a HuGE review and meta-analysis. Am J Epidemiol 2011; 173:847-857.
21. Mo Z, Gao Y, Cao Y, Gao F, Jian L. An updating meta-analysis of the GSTM1, GSTT1, and GSTP1 polymorphisms and prostate cancer: a HuGE review. Prostate 2009; 69:662-688.
22. White DL, Li D, Nurgalieva Z, El-Serag HB. Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. Am J Epidemiol 2008; 167:377-389. (Pubitemid 351264139)
23. Raimondi S, Paracchini V, Autrup H, Barros-Dios JM, Benhamou S, Boffetta P, et al. Meta-and pooled analysis of GSTT1 and lung cancer: a HuGE-GSEC review. Am J Epidemiol 2006; 164:1027-1042. (Pubitemid 44851738)
24. Langevin SM, Ioannidis JP, Vineis P, Taioli E. Assessment of cumulative evidence for the association between glutathione S-transferase polymorphisms and lung cancer: application of the Venice interim guidelines. Pharmacogenet Genomics 2010; 20:586-597.
25. Coughlin SS, Hall IJ. Glutathione S-transferase polymorphisms and risk of ovarian cancer: a HuGE review. Genet Med 2002; 4:250-257. (Pubitemid 44698559)
26. Geisler SA, Olshan AF. GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: a mini-HuGE review. Am J Epidemiol 2001; 154:95-105. (Pubitemid 32643123)
27. Martinez C, Martin F, Fernandez JM, Garcia-Martin E, Sastre J, Diaz-Rubio M, et al. Glutathione S-transferases mu 1, theta 1, pi 1, alpha 1 and mu 3 genetic polymorphisms and the risk of colorectal and gastric cancers in humans. Pharmacogenomics 2006; 7:711-718. (Pubitemid 44219401)
28. Simic T, Mimic-Oka J, Savic-Radojevic A, Opacic M, Pljesa M, Dragicevic D, et al. Glutathione S-transferase T1-1 activity upregulated in transitional cell carcinoma of urinary bladder. Urology 2005; 65:1035-1040. (Pubitemid 40693018)
29. Minelli C,Wei I, Sagoo G, Jarvis D, Shaheen S, Burney P. Interactive effects of antioxidant genes and air pollution on respiratory function and airway disease: a HuGE review. Am J Epidemiol 2011; 173:603-620.
30. Minelli C, Granell R, Newson R, Rose-Zerilli MJ, Torrent M, Ring SM, et al. Glutathione-S-transferase genes and asthma phenotypes: a Human Genome Epidemiology (HuGE) systematic review and meta-analysis including unpublished data. Int J Epidemiol 2010; 39:539-562.
31. Moyer AM, Salavaggione OE, Hebbring SJ, Moon I, Hildebrandt MA, Eckloff BW, et al. Glutathione S-transferase T1 and M1: gene sequence variation and functional genomics. Clin Cancer Res 2007; 13:7207-7216. (Pubitemid 350276908)
32. Lucena MI, Andrade RJ, Martinez C, Ulzurrun E, Garcia-Martin E, Borraz Y, et al. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2008; 48:588-596.
33. Andrade RJ, Agundez JA, Lucena MI, Martinez C, Cueto R, Garcia-Martin E. Pharmacogenomics in drug induced liver injury. Curr Drug Metab 2009; 10:956-970.
34. Agundez JA, Ladero JM. Glutathione S-transferase GSTT1 and GSTM1 allozymes: beyond null alleles. Pharmacogenomics 2008; 9:359-363. (Pubitemid 351803938)
35. Tatewaki N, Maekawa K, Katori N, Kurose K, Kaniwa N, Yamamoto N, et al. Genetic variations and haplotype structures of the glutathione S-transferase genes, GSTT1 and GSTM1, in a Japanese patient population. Drug Metab Pharmacokinet 2009; 24:118-126.
36. Piacentini S, Polimanti R, Porreca F, Martinez-Labarga C, De Stefano GF, Fuciarelli M. GSTT1 and GSTM1 gene polymorphisms in European and African populations. Mol Biol Rep 2011; 38:1225-1230.
37. Cibeira MT, de Larrea CF, Navarro A, Diaz T, Fuster D, Tovar N, et al. Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. Leuk Res 2011; 35:1178-1183.
38. Alexandrie AK, Rannug A, Juronen E, Tasa G, Warholm M. Detection and characterization of a novel functional polymorphism in the GSTT1 gene. Pharmacogenetics 2002; 12:613-619. (Pubitemid 36005670)
39. Matsuno K, Kubota T, Matsukura Y, Ishikawa H, Iga T. Genetic analysis of glutathione S-transferase A1 and T1 polymorphisms in a Japanese population. Clin Chem Lab Med 2004; 42:560-562. (Pubitemid 38779760)
40. Grau JJ, Caballero M, Campayo M, Jansa S, Vargas M, Alos L, et al. Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel. Laryngoscope 2009; 119:1484-1490.
41. Sprenger R, Schlagenhaufer R, Kerb R, Bruhn C, Brockmoller J, Roots I, et al. Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. Pharmacogenetics 2000; 10:557-565.
42. Manfredi S, Calvi D, del Fiandra M, Botto N, Biagini A, Andreassi MG. Glutathione S-transferase T1-and M1-null genotypes and coronary artery disease risk in patients with type 2 diabetes mellitus. Pharmacogenomics 2009; 10:29-34.
43. Zhao Y, Marotta M, Eichler EE, Eng C, Tanaka H. Linkage disequilibrium between two high-frequency deletion polymorphisms: implications for association studies involving the glutathione-S transferase (GST) genes. PLoS Genet 2009; 5:[Epub ahead of print].
44. Ates NA, Tursen U, Tamer L, Kanik A, Derici E, Ercan B, et al. Glutathione S-transferase polymorphisms in patients with drug eruption. Arch Dermatol Res 2004; 295:429-433. (Pubitemid 38468665)
45. Simon T, Becquemont L, Mary-Krause M, de Waziers I, Beaune P, Funck-Brentano C, et al. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther 2000; 67:432-437. (Pubitemid 30246823)
46. Watanabe I, Tomita A, Shimizu M, Sugawara M, Yasumo H, Koishi R, et al. A study to survey susceptible genetic factors responsible for troglitazoneassociated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2003; 73:435-455. (Pubitemid 36549828)
47. Oniki K, Ueda K, Hori M, Mihara S, Marubayashi T, Nakagawa K. Glutathione-S-transferase (GST) M1 null genotype and combined GSTM1 and GSTT1 null genotypes as a risk factor for alcoholic mild liver dysfunction. Clin Pharmacol Ther 2007; 81:634-635. (Pubitemid 46625110)
48. Roy B, Chowdhury A, Kundu S, Santra A, Dey B, Chakraborty M, et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol 2001; 16:1033-1037. (Pubitemid 32947147)
49. Huang YS, Su WJ, Huang YH, Chen CY, Chang FY, Lin HC, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007; 47:128-134.
50. Ramos DL, Gaspar JF, Pingarilho M, Gil OM, Fernandes AS, Rueff J, et al. Genotoxic effects of doxorubicin in cultured human lymphocytes with different glutathione S-transferase genotypes. Mutat Res 2011; 724:28-34.
51. Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005; 105:4752-4758. (Pubitemid 40807300)
52. Dirven HA, van Ommen B, van Bladeren PJ. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res 1994; 54:6215-6220. (Pubitemid 24378656)
53. Yang J, Bogni A, Schuetz EG, Ratain M, Dolan ME, McLeod H, et al. Etoposide pathway. Pharmacogenet Genomics 2009; 19:552-553.
54. He Y, Hoskins JM, McLeod HL. Copy number variants in pharmacogenetic genes. Trends Mol Med 2011; 17:244-251.
55. Lourenco GJ, Lorand-Metze I, Delamain MT, Miranda EC, Kameo R, Metze K, et al. Polymorphisms of glutathione S-transferase mu 1, theta 1, and pi 1 genes and prognosis in Hodgkin lymphoma. Leuk Lymphoma 2010; 51:2215-2221.
56. Cho HJ, Eom HS, Kim HJ, Kim IS, Lee GW, Kong SY. Glutathione-Stransferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. Cancer Genet Cytogenet 2010; 198:40-46.
57. Barahmani N, Carpentieri S, Li XN, Wang T, Cao Y, Howe L, et al. Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma. Neuro-oncol 2009; 11:292-300.
58. Naoe T, Tagawa Y, Kiyoi H, Kodera Y, Miyawaki S, Asou N, et al. Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy. Leukemia 2002; 16:203-208. (Pubitemid 34145137)
59. Rajic V, Aplenc R, Debeljak M, Prestor VV, Karas-Kuzelicki N, Mlinaric-Rascan I, et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma 2009; 50:1693-1698.
60. Erculj N, Kovac V, Hmeljak J, Dolzan V. The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma. Ann Oncol 2012; 23:961-967.
61. Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol 2010; 28:2556-2564.
62. Hohaus S, Mansueto G, Massini G, D'Alo F, Giachelia M, Martini M, et al. Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. Leuk Lymphoma 2007; 48:564-569. (Pubitemid 46499175)
63. Voso MT, D'Alo F, Putzulu R, Mele L, Scardocci A, Chiusolo P, et al. Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood 2002; 100:2703-2707.
64. Takanashi M, Morimoto A, Yagi T, Kuriyama K, Kano G, Imamura T, et al. Impact of glutathione S-transferase gene deletion on early relapse in childhood B-precursor acute lymphoblastic leukemia. Haematologica 2003; 88:1238-1244. (Pubitemid 37456378)
65. Gor PP, Su HI, Gray RJ, Gimotty PA, Horn M, Aplenc R, et al. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res 2010; 12:R26.
66. Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS, et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol 2009; 113:264-269.
67. Goekkurt E, Al-Batran SE, Hartmann JT, Mogck U, Schuch G, Kramer M, et al. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol 2009; 27:2863-2873.
68. Han X, Zheng T, Foss FM, Lan Q, Holford TR, Rothman N, et al. Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival. Am J Hematol 2010; 85:51-56.
69. Salinas-Souza C, Petrilli AS, de Toledo SR. Glutathione S-transferase polymorphisms in osteosarcoma patients. Pharmacogenet Genomics 2010; 20:507-515.
70. Ha YS, Yan C, Lym MS, Jeong P, Kim WT, Kim YJ, et al. GSTT1 as a prognosticator for recurrence and progression in patients with non-muscleinvasive bladder cancer. Dis Markers 2010; 29:81-87.
71. Tahara T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, Okubo M, et al. Effect of genetic polymorphisms related to DNA repair and the xenobiotic pathway on the prognosis and survival of gastric cancer patients. Anticancer Res 2011; 31:705-710.
72. Xiao Z, Yang L, Xu Z, Zhang Y, Liu L, Nie L, et al. Glutathione S-transferases (GSTT1 and GSTM1) genes polymorphisms and the treatment response and prognosis in Chinese patients with de novo acute myeloid leukemia. Leuk Res 2008; 32:1288-1291. (Pubitemid 351626919)
73. Erculj N, Kovac V, Hmeljak J, Dolzan V. The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma. Ann Oncol 2012; 23:961-967.
74. Mossallam GI, Abdel Hamid TM, Samra MA. Glutathione S-transferase GSTM1 and GSTT1 polymorphisms in adult acute myeloid leukemia; its impact on toxicity and response to chemotherapy. J Egypt Natl Canc Inst 2006; 18:264-273.
75. Muller P, Asher N, Heled M, Cohen SB, Risch A, Rund D. Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups. Leuk Res 2008; 32:919-929.
76. Jones BA, Christensen AR, Wise JP Sr., Yu H. Glutathione S-transferase polymorphisms and survival in African-American and white colorectal cancer patients. Cancer Epidemiol 2009; 33:249-256.
77. Funke S, Timofeeva M, Risch A, Hoffmeister M, Stegmaier C, Seiler CM, et al. Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy. Pharmacogenomics 2010; 11:33-41.
78. Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH, Lee JH, et al. BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci 2010; 101:1247-1254.
79. Ott K, Lordick F, Becker K, Ulm K, Siewert J, Hofler H, et al. Glutathione-Stransferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients. Int J Colorectal Dis 2008; 23:773-782.
80. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94:936-942. (Pubitemid 34778092)
81. Medeiros R, Pereira D, Afonso N, Palmeira C, Faleiro C, Afonso-Lopes C, et al. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 2003; 8:156-161. (Pubitemid 36897285)
82. Woo MH, Shuster JJ, Chen C, Bash RO, Behm FG, Camitta B, et al. Glutathione S-transferase genotypes in children who develop treatmentrelated acute myeloid malignancies. Leukemia 2000; 14:232-237. (Pubitemid 30095376)